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conducted probabilistic sensitivity analysis. ConClusions: The cost-effectiveness 
of a lung cancer screening program varies widely and seems to largely depend on 
several key model parameters. Improved risk stratification might enhance the cost-
effectiveness of such a program.
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reversal
Holdford D.A.
Virginia Commonwealth University, Richmond, VA, USA
objeCtives: Evzio is a naloxone autoinjector indicated for lay overdose reversal in 
emergency treatment of known or suspected opioid overdose. The cost effectiveness 
of prescribing Evzio for “lay overdose reversal” was compared to “no lay reversal” 
using a health system perspective over one year. Methods: A decision analysis 
model was built using outcomes data obtained from randomized clinical trials and 
publicly available cost data. Adults at risk of heroin overdose in the US were included 
in the model. The primary outcome was Quality Adjusted Life Year (QALY). All data 
were subject to sensitivity analyses. Results: In the base case analysis, Evzio was 
found to cost health systems an extra $24,126 for every additional QALY saved due 
to overdose. Sensitivity analyses of variables found that the model was sensitive to 
the probability of emergency medical services being called if no Evzio was given, 
the probability of an overdose being witnessed, and the probability of survival if 
no medical treatment was given. ConClusions: The cost per QALY saved in pre-
scribing the naloxone autoinjector, Evzio, for patients at risk of opiate overdose is 
within acceptable cost effectiveness values for new therapies. When administered 
by friends, family members, and other witnesses of an opioid overdose, Evzio can 
be cost-effective.
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objeCtives: Atrial fibrillation (AF) is an arrhythmia that increases stroke risk. 
Left atrial appendage (LAA) occlusion with a LAA closure device is the first non-
pharmacologic strategy to undergo randomized, warfarin-controlled trials. It has 
demonstrated non-inferiority to the current standard, warfarin, for stroke and 
systemic embolism prevention. The objective of this study was to evaluate the 
cost-effectiveness of LAA closure relative to chronic warfarin therapy for stroke 
prevention in AF patients at elevated stroke risk. Methods: A Markov model was 
constructed from the payer perspective assuming a cohort of AF patients aged 65 
with a CHADS2 score≥ 2 at model entry. Clinical inputs were obtained from pub-
lished trials. Utilities were obtained from published studies assessing quality-of-
life in AF patients. Costs were obtained from published literature. Using quarterly 
cycles, the model was run over the patients’ remaining lifetime summing total costs 
and total quality-adjusted-life-years (QALYs) for each arm. Results: Total QALYs 
gained for the warfarin and device arms were 11.58 and 11.76, respectively. Total 
costs for the warfarin and device arms were $84,100 and $89,400, respectively. The 
base-case ICER for LAA closure compared to warfarin was $29,600/QALY. The model 
was most sensitive to underlying rates of stroke and intracranial hemorrhage (ICH) 
and the relative risk of stroke and ICH in the device arm compared to warfarin. It 
was relatively robust to costs and utilities. Monte Carlo simulation with 10,000 itera-
tions demonstrated LAA closure was cost-effective in 50% and 54% of simulations 
at thresholds of $50,000/QALY and $100,000/QALY. ConClusions: Though not yet 
available in the US, trial data suggests LAA closure is an option for anticoagulant-
eligible AF patients. It is estimated to be cost-effective at previously acceptable 
willingness-to-pay thresholds, but uncertainty around the ICER suggests a need 
for more precise parameter estimates. It remains a novel mechanism to improve 
outcomes in undertreated AF patients.
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objeCtives: Efforts to reduce the tuberculosis (TB) burden in many countries 
have recently focused on screening high-risk groups for latent TB infection (LTBI). 
Clinicians generally use the tuberculin skin test (TST) or interferon-gamma release 
assay (IGRA) to aid in LTBI diagnosis. We performed a systematic review of cost-
utility analyses in this area. Methods: Five electronic databases were used to iden-
tify studies. Study quality was assessed using the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS). Population, setting, model type, perspec-
tive, costs, screening and treatment parameters, and incremental cost-effectiveness 
ratios (ICERs) were extracted. All costs were adjusted to 2013 US dollars, with ICERs 
< $20,000 considered highly cost-effective, ICERs between $20,000 and $100,000 
moderately cost-effective, and ICERs > $100,000 not cost-effective. Results: Of 
415 studies identified, 8 were included in the analysis, with 7 using Markov mod-
els and 1 using decision analysis. The decision to screen and how to screen for 
LTBI was evaluated in 5 studies, while the remaining three only evaluated how 
to screen. Perspectives used were societal (n= 4), healthcare program (n= 2), and 
healthcare system (n= 2). Studies evaluating immigrants found adult screening 
highly cost-effective with a TST (n= 1) and moderately cost-effective with an IGRA 
(n= 1). Screening of the foreign-born (n= 1) was moderately cost-effective with an 
IGRA until 44 years of age. Screening for HIV was found to be highly cost-effective 
with a TST (n= 3) and moderately cost-effective with an IGRA (n= 1). Screening in 
those with renal diseases (n= 2) and diabetes (n= 1) was found to be not cost-effec-
tive; screening in other immunocompromised populations was not cost-effective 
(n= 1). ConClusions: Screening of HIV patients with a TST is highly cost-effective 
and screening of immigrants and foreign-born with an IGRA is moderately cost-
sant medication for the treatment of adults with MDD who have failed at least two 
adequate courses of antidepressants. Methods: A three-year Markov microsimu-
lation model with two-month cycles was used to compare the costs and quality-
adjusted life years (QALYs) of rTMS and a mix of antidepressants (including selective 
serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, 
tricyclics, noradrenergic and specific serotonergic antidepressants and monoam-
ine oxidase inhibitors). The model synthesized data sourced from a meta-analysis, 
published literature, national cost reports and expert opinions. Incremental cost-
utility ratios were calculated and uncertainty of the results was assessed using 
univariate and probabilistic sensitivity analyses. Results: Compared with anti-
depressant medication therapy, rTMS is a dominant/cost-effective alternative for 
patients with treatment-resistant depressive disorder. The model predicted that 
QALYs gained with rTMS was higher than for antidepressant medications (1.25 ver-
sus 1.18 QALYs) while costs were slightly less (AUD 31,003 versus AUD 31,190). The 
treatment response rate, using the Hamilton Depression Rating Scale 17, was 16.8% 
for antidepressant medications and 37.5% for rTMS. In the Australian context at the 
willingness-to-pay threshold of AUD 50,000 per QALY gain, the probability that rTMS 
was cost-effective was 73%. Sensitivity analyses confirmed the model stability and 
superiority of rTMS compared with antidepressant medications. ConClusions: 
While both antidepressant medications and rTMS are clinically effective treatments 
for MDD, rTMS is shown to outperform antidepressants in terms of cost-utility 
for patients who have failed at least two adequate courses of pharmacotherapies. 
The study shows that rTMS is a cost-effective therapy alterative for patients with 
treatment-resistant depression without the many side-effects of pharmacotherapy.
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objeCtives: Patients with non-ST elevation myocardial infarction are managed 
based visual assessment of coronary angiography, which can be inaccurate and 
subjective. A randomized pilot trial has investigated an alternative approach using 
physiology-guided management with fractional flow reserve that may optimize 
outcomes. Objective was to estimate the cost-effectiveness of FFR-guided manage-
ment vs. coronary angiography. Methods: A trial-based economic evaluation was 
conducted (n= 350). We adopted a UK National Health Service perspective. Part I of 
the analysis used raw, unadjusted costs and QALYs assembled using individual 
resource use and EQ5D responses from the RCT. Part II used statistical modelling 
to model the effect pathway of FFR by conditioning total costs and QALYs on the 
treatment decision (coronary artery bypass graft (CABG), medical therapy and per-
cutaneous coronary intervention (PCI)). Results were then applied to treatment 
decision distributions following FFR or standard care management. Uncertainty in 
GLM coefficients, unit cost parameters and sampling were incorporated using boot-
strapping and Monte Carlo methods. Results: FFR reduced revascularization by PCI 
or CABG (OR 0.52; 95%CI: 0.28 – 0.94; p= 0.022). Part I: FFR led to a mean cost savings 
(£8,253 vs. £8,603; difference: –£305 [SD= £519]). Likely drivers of cost savings were 
length of stay (-£331 [£342]) and index year health events (-£217 [£223]). However, 
low information size contributed to their large imprecision. Incremental QALYs 
were comparable (0.811 vs. 0.799; diff: 0.013 [0.023]). Part II: FFR led again to a mean 
cost savings (£8,328 vs. £8,532; difference: –£204 [£305]) and comparable incremen-
tal QALYs (0.801 vs. 0.806; diff: –0.005 [0.004]). The probability of cost-effectiveness 
remained comparable over common willingness-to-pay (70-75%). ConClusions: 
Early evidence suggests FFR may be cost saving and comparable in QALYs. However, 
considerable uncertainty persists. We also prescribe specific design considerations 
for a future trial, including information size suggestions, follow-up frequency and 
outcomes to aid modelling/lifetime extrapolation.
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objeCtives: Lung cancer is the leading cause of cancer related mortality in North 
America. This is attributable to it often being diagnosed at an advanced stage. Low 
dose computed tomography (LDCT) is a tool that can be used to potentially detect 
lung cancer at an earlier stage thereby improving patient outcomes. Recently, the 
National Lung Screening Trial (NLST) has shown that this method of screening 
can produce significant mortality reductions; however, whether such a program is 
cost-effective has not yet been well-established. Methods: We searched MEDLINE, 
EMBASE, EBM Reviews - Health Technology Assessment, the National Health Service 
(NHS) Economic Evaluation Database, and the Cochrane Database of Systematic 
Reviews. We included studies that presented a cost-effectiveness analysis of LDCT as 
a method of screening for lung cancer. Studies published prior to 2000 were excluded 
based on advances in imaging technologies. Costs are presented in 2012 United 
States dollars. Results: Thirteen studies were identified that met the criteria for 
inclusion. Ten studies were from the United States, and one each from Australia, 
Israel, and Japan. Most studies evaluated an annual screening program while four 
studies evaluated one time only screening. Incremental cost-effectiveness ratios 
(ICERs) were extracted for comparison and varied markedly between $8 186/LYG to 
$195 758/LYG (life year gained) or for quality-adjusted life years (QALYs): $1 494/QALY 
to $150 772/QALY. The model results seemed to be sensitive to several parameters 
including: the prevalence of lung cancer, the cost of LDCT screening, inclusion and 
characteristics of a smoking cessation program, the stage at which lung cancer was 
detected, and the lead-time associated with screening. Only one identified study 
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with ICD-9 diagnosis codes for stroke/TIA had their diagnostic imaging utilization 
summarized within ±3 days of the stroke/TIA event. Results: A total of 18,770 
matched patients were identified; average age 65.5 (13.38 SD) and 21.9% female. 
When comparing patients that had at least one diagnostic procedure within the 
year, ICD patients had significantly less imaging overall [5.4 (6.38 SD) vs. 6.8 (8.18 
SD), p< 0.0001]. Among patients with records of stroke/TIA (ICD 5%, non-implant 
4%) and accompanying diagnostic imaging, 44% of non-implant patients underwent 
magnetic resonance imaging (MRI) vs. 1% of ICD patients (p< 0.0001) and had more 
imaging tests overall (4.1 (2.47 SD) vs. 3.2 (2.16 SD), p< 0.0001). ConClusions: MRI 
utilization is lower in ICD patients compared to non-implant patients. One in 20 ICD 
patients require imaging for a recorded stroke/TIA and less than 1% received MRI 
for this indication. The burden of incident stroke/TIA in contemporary ICD patients 
may justify consideration of MRI conditional devices in the majority of ICD patients.
MeDiCal DeviCe/DiagnostiCs - Patient-reported outcomes & Patient  
Preference studies
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objeCtives: This study aimed to compare and evaluate the health-related quality of 
life (HRQOL) in Asian end-stage renal disease (ESRD) patients treated with continu-
ous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) 
in Singapore. Methods: Data used in this study were from two cross-sectional 
surveys conducted between 2009 and 2013. Participants were recruited from the 
PD centers of Singapore General Hospital and National University Hospital. The 
inclusion criteria were ESRD patients who have been on PD for at least 3 months 
and at least 21-year-old. In both surveys, participants completed the Kidney Disease 
Quality of Life (KDQOL) instrument and questions assessing socio-demographic 
characteristics. Co-morbidities, clinical, and dialysis-related variables (i.e. vintage, 
dialysis adequacy, dependency status [self-cared/assisted]) were retrieved from 
medical records. The 36-item KDQOL (KDQOL-36) was used to generate two generic 
summary scores (physical component summary [PCS], mental component sum-
mary [MCS]), three disease-specific scales (symptoms, effects, burden), and two 
health utility scores (Short Form 6-Dimension [SF-6D] and EuroQol 5-Dimension 
[EQ-5D]). The HRQOL of patients treated with CAPD and APD measured by the above-
mentioned scales was compared using separate linear regression models with 
and without adjustment of variables collected. Results: Of the 382 PD patients 
approached, 266 were eligible and agreed to participate: 145 on CAPD (mean age: 60.8 
years; female: 54.5%) and 121 on APD (mean age: 57.4 years; female: 54.5%). Without 
adjustment, the HRQOL of CAPD and APD patients were similar according to all 
measures except for KDQOL symptoms (difference: 6.2, p< 0.01). With adjustments, 
significant differences were observed in KDQOL symptoms (7.0, p< 0.01) and PCS 
(2.8, p< 0.05) between CAPD and APD patients, suggesting that APD was associated 
with milder dialysis-related symptoms and better physical health. ConClusions: 
It appears that APD patients experience better HRQOL in some domains than CAPD 
patients in Singapore, although generic utility measures are not sensitive to this 
treatment advantage.
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objeCtives: This study aimed at assessing patient preferences for different char-
acteristics of Dry Powder Inhalers (DPIs) from patients with asthma and chronic 
obstructive pulmonary (COPD) disease in France. Methods: Attributes character-
izing DPIs and attribute levels were defined using focus groups among asthma and 
COPD patients and interviews of health care professionals, previously reported. 
Those attributes were ease of use, accurate and easy-to-read dose counter, dose 
confirmation, hygiene of the mouthpiece, flexibility of device handling and use with 
breathing difficulties. A survey was conducted among asthma and COPD patients to 
elicit patients’ preferences and willingness to pay using the discrete choice experi-
ment (DCE) method. A fractional factorial design including 3 sets of 12 choices was 
created. Each choice was made in two steps: a choice between two fictitious inhal-
ers then between preferred inhaler and current inhaler. Analyses were performed 
using a ranked ordered logit model. Interactions between attributes and asthma/
COPD were tested. Results: Participants included 201 patients with asthma and 60 
with COPD. Asthma patients were on average 40 years old and COPD patients were 
51 year old. Patients were willing to pay € 4.70 per month (standard error: € 0.49) for 
an inhaler requiring one step to prepare a dose instead of four, € 3.62 (€ 0.61) for an 
accurate dose counter compared to a less precise one, € 3.27 (€ 0.48) for an inhaler 
giving confirmation that the dose has been taken, € 1.02 (€ 0.38) for flexibility of han-
dling and € 4.79 (€ 0.73) to be able to use the inhaler in case of breathing difficulties. 
Preferences of patients with asthma and COPD are largely similar. ConClusions: 
Patients with asthma and COPD place highest values on the ease of use and abil-
effective. Screening of other immunocompromised populations is cost-prohibitive, 
however with minimal well-designed studies using consistent assumptions and 
parameters, these Conclusions should be interpreted cautiously.
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objeCtives: To estimate the cost attributed to productivity loss due to patient’s 
hospitalization, in patients subjected to pacemaker (PM) and implantable cardi-
overter-defibrillator (ICD) implantation. Methods: A single-center, prospective, 
cost-of-illness study was conducted for one year period. In total, 464 consecutive 
patients were recruited. 370 were subjected to PM implantation, (240 initials, 130 
replacements) and 94 to ICD (80 initials, 14 replacements). Data were assessed at 
patients’ enrolment in the study and at 6th and 12th months after the implanta-
tion. Then, the cost attributed to productivity loss due to patient’s hospitalization, 
was calculated using a bottom-up approach. Results: The mean (95% confidence 
interval) cost attributed to productivity loss for the PM recipients was found to be 
€ 39 (€ 25–€ 53). € 43 (€ 26–€ 64) for the patients who were subjected to initial implanta-
tion and € 30 (€ 12–€ 57) for the patients subjected to replacement. In one year follow 
up for the patients who were subjected to PM implantation the mean cost was € 71 
(€ 70–€ 72), € 71 (€ 70–€ 73) for the patients who were subjected to initial implantation 
and € 70 (€ 70–€ 70) for the patients subjected to replacement. For the ICD recipi-
ents was found to be € 186 (€ 119–€ 268), € 207 (€ 130–€ 303) for the patients who were 
subjected to initial implantation and € 53 (€ 0–€ 140) for the patients who were 
subjected to replacement. In one year follow up for ICD recipients the mean cost 
was € 367 (€ 72–€ 802), € 414 (€ 73–€ 926) for the patients who were subjected to initial 
implantation and € 70 (€ 70–€ 70) for the patients who were subjected to replace-
ment. ConClusions: The study provides unique data regarding the cost attrib-
uted to productivity loss of CRMD recipients in Greece. The mean cost attributed to 
productivity loss, in the case of ICD recipients is much higher than in PM recipients.
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objeCtives: Advances in ultrasound technology and training have made it possible 
for physicians to conduct detailed imaging studies in an office setting. Ultrasound 
images make it possible to visualize subclinical evidence of disease activity quickly 
and could contribute to prompt initiation of therapy in patients with rheumatoid 
arthritis (RA). The objectives of this study were to describe the use and cost of 
ultrasound in patients with a confirmed diagnosis of RA, in the United States, over 
the last decade. Methods: Patients were selected from a large national private 
insurance-claims database if they had at least 2 claims for ICD-9 code 714.xx at 
least 45 days apart and received Disease-Modifying Antirheumatic Drug therapy 
between 2002 and 2013. The CPT codes 7880-7882 were used to identify ultrasound 
procedures. Descriptive statistics were used and simple hypothesis tests per-
formed. Results: A cohort of 129,005 patients with RA was selected for this study. 
Patients who received ultrasounds were significantly (p < 0.01) more likely to be 
younger, female, have point-of-service insurance, and live outside the Midwest. 
Between 2002 and 2013, there was a > 1900% increase in the use of ultrasound in 
this patient population, from 73 procedures in 2002 to 1448 procedures in 2013. 
During this same period, the mean cost of the ultrasound procedure fluctuated 
over time; the cost increased 35% to a high of $216 (2013 USD) in 2008 and then 
decreased starting after 2010 down 32% by 2013 to $146 (2013 USD). Rheumatologists 
performed 70% of the procedures. ConClusions: This research clearly shows that 
use of ultrasound, primarily by rheumatologists, has been increasing. The data also 
show that patients who received ultrasounds may be different than those who did 
not receive the procedure. Further research is needed to evaluate the impact ultra-
sounds may have on treatment decisions, access to biologics, and patient outcomes.
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objeCtives: We examined diagnostic imaging utilization across all medical 
conditions and in the case of acute stroke in patients with implantable cardio-
verter defibrillators (ICD) and a propensity matched cohort without record of any 
devices. Methods: This study used data from MarketScan® Commercial Claims 
and Medicare Supplemental database (Truven Health Analytics, New York, NY). 
Patients with continuous health plan enrollment in the calendar year 2012 with 
and without ICDs were identified. Patients in the ICD group were matched 1:1 using 
direct (age, gender and type of insurance plan) and propensity score matching 
(comorbid conditions) to patients with no record of device implantation. Diagnostic 
imaging utilization was compared across the matched cohorts, in total and by imag-
ing category, for the calendar year 2012. The same comparison was carried out 
for the stoke/TIA sub-population of interest. For the calendar year 2012, patients 
